Maite Bourlon
@BourlonMaite
Oncology | Urologic Oncology @incmnszmx IDEA Award | Global Oncology TF @ASCO| Fellow @JCOGO_ASCO @oncofertilty LATAM @UPMex WWCC Award @ConquerCancerFd
ID:1020128956475817985
20-07-2018 02:11:11
666 Tweets
2,4K Followers
1,7K Following
Go check out our recent #MOASC2024 poster presentations. So honored to be working with such outstanding group of phyisicans. Thank you Oncology Tube Sumanta K. Pal, MD, FASCO for this opportunity to share our insights with the community
oncologytube.com/inspiring-inno…
Fin del Curso de Uro-oncología 2023-2024
Muchas felicidades Dr Mauricio Mora y Dra María Fernanda Rodríguez Mafer
Estamos orgullosos Yuly A. Remolina Maite Bourlon Dirección de Enseñanza del INCMNSZ INCMNSZ HEM ONC INCMNSZ INTERNAL MEDICINE Nayeli Adeline Thomas Flaig
SOC Role of Frontline Nivolumab Plus Cabozantinib in Metastatic RCC Confirmed With Long-Term Efficacy Results Maite Bourlon ASCO #GU24 #oncology #MedTwitter #rcc
onclive.com/view/soc-role-…
💫🌟👏🔝 Kudos!! to 👩🎓Maite Bourlon for a crystal-clear presentation! at #GU24 ASCO
🔥 New #CheckMate9ER 55-Month Update!
📊 Nivolumab + Cabozantinib vs Sunitinib in aRCC
📈 Superior PFS, OS, ORR with N+C
🕒 Median PFS: 16.4 vs 8.4 months
⏳ Median OS: 46.5 vs 36.0 months
🎯…
Brillant presentation of CM-9ER by Maite Bourlon
Long-term follow-up shows success for Nivo+Cabo in aRCC treatment, hitting high notes in PFS, OS, and ORR compared to Sunitinib, especially for IMDC inter/poor group.
ASCO #GU24 OncoAlert UroToday.com Toni Choueiri, MD Emre Yekedüz…
ASCO #GU24 Maite Bourlon presenting the 55 month of Checkmate 9ER. Consistent safety and efficacy.
Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Moshe Ornstein MD Tian Zhang, MD, MHS
And now Maite Bourlon reporting updated efficacy from #CM9ER
👉55.6 mo median follow-up
👉 maintained efficacy benefit of Nivo+Cabo over Sunitinib
👉No new safety signal observed
ASCO #GU24 OncoAlert OncLive.com
Amazing and extremely smart discussion by Pedro C Barata, MD MSc FACP about the updated & challenging landscape in adjuvant high-risk RCC #GU24
Pedro, You deserve a trophy 🏆!!!!
Big congrats!!!! By the way, I loved the mention to Maite Bourlon 😜
OncoAlert
Enrique Grande Pedro C Barata, MD MSc FACP OncoAlert I loved the mention too! Pedro C Barata, MD MSc FACP It is more and more a quandary in clinical grounds!!! 🦀👩🏻⚕️👨🏻⚕️🌍